Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort.

doi:10.1016/j.clcc.2024.12.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort.

Clinical colorectal cancer - 1 Jun 2025

Lucchetti Jessica, Angotti Lorenzo, Parisi Alessandro, Basso Michele, Polito Mariam Grazia, Zoratto Federica, Di Giacomo Emanuela, Nitti Daniele, Minelli Alessandro, Salvatore Lisa, Calegari Maria Alessandra, Lo Prinzi Federica, Gemma Donatello, Signorelli Carlo, Veroli Margherita, Anghelone Annunziato, Galbato Muscio Luca, Di Cocco Barbara, Trombetta Giorgio, Morelli Cristina, Schietroma Francesco, Vincenzi Bruno, Cortellini Alessio, Tonini Giuseppe

Abstract excerpt

BACKGROUND: Both aflibercept and bevacizumab-based regimens are available II-line treatment options for patients with metastatic colorectal cancer (mCRC). However, no head-to-head trials established the optimal anti-angiogenic strategy for this setting. METHODS: We launched a multicenter, retrospective, observational study to assess and compare clinical efficacy of II-line treatments for patients with mCRC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to GTP Phosphohydrolases

Share to Progression-Free Survival

Share to Propensity Score

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptors, Vascular Endothelial Growth Factor

Source

Open in PubMed

Identifiers

PMID: 39856001
DOI: 10.1016/j.clcc.2024.12.007

Genes

KRAS
NRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort.PMID 39856001Read ↗

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.Semantic proximity Read ↗

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.Semantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled AnalysisSemantic proximity Read ↗

Effect of Antiangiogenic-Based Treatment and Systemic Inflammatory Factors on Outcomes in Patients With BRAF v600-Mutated Metastatic Colorectal Cancer: A Real-World Study in SpainSemantic proximity Read ↗

Clinicopathologic features and treatment efficacy of patients with BRAF V600E-mutated metastatic colorectal cancer: a multi-center real-world propensity score matching study.Semantic proximity Read ↗

Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study.Semantic proximity Read ↗

Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.Semantic proximity Read ↗

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).Semantic proximity Read ↗

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.Semantic proximity Read ↗

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.Semantic proximity Read ↗

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.